Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1514


Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.

Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D.

Clin Cancer Res. 2009 Jul 1;15(13):4467-74. doi: 10.1158/1078-0432.CCR-09-0582. Epub 2009 Jun 16.


One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.

Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2005 Feb 1;174(3):1751-9.


NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.

Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.

Cancer Res. 2002 Jan 1;62(1):213-8.


HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.

Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M.

Clin Cancer Res. 2009 Jan 1;15(1):299-306. doi: 10.1158/1078-0432.CCR-08-1747.


Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.

Karbach J, Pauligk C, Bender A, Gnjatic S, Franzmann K, Wahle C, Jäger D, Knuth A, Old LJ, Jäger E.

Int J Cancer. 2006 Feb 1;118(3):668-74. Erratum in: Int J Cancer. 2006 Oct 1;119(7):1753.


Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.

Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A.

J Exp Med. 2000 Feb 21;191(4):625-30.


A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.

Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W.

Cancer Res. 2009 Feb 1;69(3):1046-54. doi: 10.1158/0008-5472.CAN-08-2926. Epub 2009 Jan 27. Erratum in: Cancer Res. 2009 May 15;69(10):4553.


Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.

Ohkuri T, Sato M, Abe H, Tsuji K, Yamagishi Y, Ikeda H, Matsubara N, Kitamura H, Nishimura T.

Cancer Sci. 2007 Jul;98(7):1092-8. Epub 2007 May 4.


Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.

Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S.

J Immunol. 2004 Apr 15;172(8):5095-102.


NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM.

Cancer Res. 2000 Sep 1;60(17):4946-52.


A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.

Ayyoub M, Souleimanian NE, Godefroy E, Scotto L, Hesdorffer CS, Old LJ, Valmori D.

Clin Immunol. 2006 Feb-Mar;118(2-3):188-94. Epub 2005 Dec 20.


Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42. Epub 2007 Jul 25.


Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.

Garcia Casado J, Janda J, Wei J, Chapatte L, Colombetti S, Alves P, Ritter G, Ayyoub M, Valmori D, Chen W, Lévy F.

Eur J Immunol. 2008 Jul;38(7):1867-76. doi: 10.1002/eji.200737923.


CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.

Gnjatic S, Jäger E, Chen W, Altorki NK, Matsuo M, Lee SY, Chen Q, Nagata Y, Atanackovic D, Chen YT, Ritter G, Cebon J, Knuth A, Old LJ.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11813-8. Epub 2002 Aug 19.


In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.

Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E.

Clin Cancer Res. 2006 Mar 15;12(6):1921-7.


Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.

Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.

Eur J Immunol. 2004 Oct;34(10):2919-29.


Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.

Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee HG, Pfreundschuh M.

Cancer Immunol Immunother. 2004 Jul;53(7):589-99. Epub 2004 Jan 23.


Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.

Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jäger E.

Int J Cancer. 2010 Feb 15;126(4):909-18. doi: 10.1002/ijc.24850.


Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.

Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S.

J Immunother. 2008 Nov-Dec;31(9):849-57. doi: 10.1097/CJI.0b013e3181891574.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk